𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A recommended scale for cognitive screening in clinical trials of Parkinson's disease

✍ Scribed by Kelvin L. Chou; Melissa M. Amick; Jason Brandt; Richard Camicioli; Karen Frei; Darren Gitelman; Jennifer Goldman; John Growdon; Howard I. Hurtig; Bonnie Levin; Irene Litvan; Laura Marsh; Tanya Simuni; Alexander I. Tröster; Ergun Y. Uc

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
88 KB
Volume
25
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD. © 2010 Movement Disorder Society

📜 SIMILAR VOLUMES

Parkinson's disease-cognitive rating sca
Parkinson's disease-cognitive rating scale: A new cognitive scale specific for Parkinson's disease
✍ Javier Pagonabarraga; Jaime Kulisevsky; Gisela Llebaria; Carmen García-Sánchez; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 1 views

## Abstract Cognitive defects associated with cortical pathology may be a marker of dementia in Parkinson's disease (PD). There is a need to improve the diagnostic criteria of PD dementia (PDD) and to clarify the cognitive impairment patterns associated with PD. Current neuropsychological batteries

PDD-Short Screen: A brief cognitive test
PDD-Short Screen: A brief cognitive test for screening dementia in Parkinson's disease
✍ Javier Pagonabarraga; Jaime Kulisevsky; Gisela Llebaria; Carmen García-Sánchez; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 1 views

## Abstract The diagnosis of Parkinson's disease with dementia (PDD) is currently based on clinical criteria (DSM‐IV, MDS–Task Force). In daily practice and research studies, these criteria still depend on the subjective impression of the examiner. Brief screening tests (BST) are helpful in identif

The montreal cognitive assessment as a s
The montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease
✍ David J. Gill; Arielle Freshman; Jennifer A. Blender; Bernard Ravina 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB

## Abstract Cognitive impairment is common in Parkinson's disease (PD) and can occur early in the disease course. No effective screening test exists for detection of early or mild cognitive impairment in PD. We examined the Montreal Cognitive Assessment (MoCA) as a screening tool for cognitive dysf

French recommendations for clinical drug
French recommendations for clinical drug trials in cognitive disorders of the elderly
✍ Dr. Bernard Michel; Roland Sambuc; Jean-Claude Scotto 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 449 KB 👁 2 views

## Abstract A consensus conference on the topic of clinical drug trials in cognitive disorders of the elderly was held in Marseille on January 28–29, 1993. At the end of this conference, several recommendations were made. Drugs used in trials must be chosen according to solid neurobiological eviden

Impact of placebo assignment in clinical
Impact of placebo assignment in clinical trials of Parkinson's disease
✍ Christopher G. Goetz; Kimberly Janko; Lucy Blasucci; Jean A. Jaglin 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 1 views

## Abstract Informed consent procedures in placebo‐controlled trials are developed to ensure that subjects entering studies clearly understand the possibility of placebo assignment. The extent of patient understanding and the impact of learning that they were assigned placebo treatment have not bee

Interpreting the results of Parkinson's
Interpreting the results of Parkinson's disease clinical trials: Time for a change
✍ Nick H. G. Holford; John G. Nutt 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 1 views

## Abstract Randomized clinical trials testing putative disease‐modifying agents in Parkinson's disease (PD) have yielded controversial results that have not influenced evidence‐based recommendations for the treatment of PD. We argue that the failure of these clinical trials may be linked to end po